Microbial therapeutics: New opportunities for drug delivery
Name
JEM_20190609.pdf
Description
Published version
Size
703.56 KB
Format
Adobe PDF
Checksum (MD5)
81985ece26b214ca133739a46772e045
Author(s)
Jimenez, Miguel
Langer, Robert S
Traverso, Carlo Giovanni
Date Issued
April 2019
Journal
Journal of Experimental Medicine
Publisher
Rockefeller University Press
Citation
Jimenez, Miguel et al. "Microbial therapeutics: New opportunities for drug delivery." Journal of Experimental Medicine 216, 5 (April 2019): 1005–1009 © 2019 MIT
Version
Final published version
Abstract
With >40 clinical trials underway, we are nearing the first FDA-approved live microbial therapeutic. Here, Giovanni Traverso, MIT and Harvard Medical School Assistant Professor, and colleagues Miguel Jimenez and Institute Professor Robert Langer from MIT discuss the significant challenges of administering live microorganisms to patients and the opportunities for drug delivery of these new complex therapeutics.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Chemical Engineering
Massachusetts Institute of Technology. Department of Mechanical Engineering
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1084/jem.20190609
